Epstein-Barr Virus and Human Disease · 1990

Front Matter....Pages i-xliv
Front Matter....Pages 1-1
Replication of the Epstein-Barr Virus in Lymphoid and Epithelial Cells....Pages 3-12
The Productive Cycle Defect in Raji EBV is not Solely Due to Absence of the Balf2 Gene....Pages 13-18
 Interference of EBNA-1 Binding to Ori-P by Cellular Proteins (ANTI-EBNA1) ....Pages 19-25
How Zebra, A Weak Transactivator, Exerts Strong Biologic Effects....Pages 27-42
EBNA-2 Transactivation of CD23....Pages 43-46
EBNA-2 Transactivation of LMP1....Pages 47-51
A New Lymphoid-Specific Epstein-Barr Virus Enhancer is Transactivated by EBNA-2....Pages 53-57
Transcriptional Regulation of an Epstein-Barr Virus Nuclear Antigen Gene Promoter....Pages 59-63
EBNA-2 Influences Promoter Function in Burkitt Lymphoma Cells....Pages 65-67
Functional Characterization of Epstein-Barr Virus DNA Polymerase by in Vitro Transcription-Translation of Cloned Genes....Pages 69-73
Epstein-Barr Virus Recombinants: Use of Positive Selection Markers to Rescue Mutants in EBV Negative B Lymphoma Cells....Pages 75-79
Characterization of EBV DNase Related Transcripts....Pages 81-85
The Pst I-Repeats of the Epstein-Barr Virus Encode a Protein with a Molecular Weight Between 115,000 and 140,000....Pages 87-91
The EBV BRLF1 Protein Has Sequence And Functional Similarity With The C-myb Oncogene....Pages 93-97
Heterodimers of the Zebra and Fos Basic Domains Bind DNA with the Specificity of Zebra....Pages 99-103
Relationship of the EBV Lytic Activator Zta to the bZIP Family of Cellular Transactivators....Pages 105-109
Trans-regulation of the Early MS Gene of EBV and Its Dependence on the Host Cell....Pages 111-115
Induction and Regulation of Expression of the Epsteinbarr Virus DNA Polymerase Gene....Pages 117-121
Recombinant EBV Antigens and Their Diagnostic Value....Pages 123-125
Epstein-Barr Virus Associated Histio-Lymphoproliferative Syndromes in Two European Families....Pages 127-130
Front Matter....Pages 131-131
Role of Cytokines in EBV-Infected Cell Growth....Pages 133-142
Epstein-Barr Virus Variants at Mucosal Surfaces....Pages 143-146
Epstein-Barr Virus Infection and Monokine Synthesis....Pages 147-151
Transcription from Bam HI A in NPC....Pages 153-156
Characterisation of the Novel “18.8” Family of Transcripts from NPC Tumours....Pages 157-161
EBER1 Small Nuclear RNA in Malignancy: A Morphologically Distinctive Target for Detection of EBV in Formalin-Fixed Paraffin-Embedded Specimens....Pages 163-167
Tumorigenicity and Organization of the Terminal Region of the Epstein-Barr Virus (EBV) Genome in LCLs Derived from Carcinogen-Treated Lymphocytes....Pages 169-173
Expression of EBNA2 and an EBNA5 Protein from Alternatively Spliced mRNA’s....Pages 175-180
Front Matter....Pages 181-181
EBV Humoral Immunology: 1966–1990....Pages 183-189
The Role of EBNA Proteins as a Target for EBV-Specific T Cell Lysis....Pages 191-200
Role of the Epstein-Barr Virus (EBV) Glycoprotein GP350 as a Target Antigen for EBV-Specific Cellular Killing....Pages 201-206
Mapping of B and T Cell Epitopes on the Epstein-Barr Virus Receptor Ligand Gp340: A Candidate Subunit Vaccine....Pages 207-211
Identification of T Helper Cell Epitopes On gp340....Pages 213-217
Reactivity of EBV Type A-Specific Cytotoxic T-Cells....Pages 219-223
DNA Sequence Variation in EBV-Encoded T-Cell Epitopes....Pages 225-229
Recombinant Adenoviruses Which Express the EBV Major Membrane Antigen GP340/220 Induce Persistent EBV-Neutralizing Antibodies in Rabbits....Pages 231-236
Inhibition of the EBV Lytic Cycle by Sequence Specific Antisense Oligonucleotides....Pages 237-240
Front Matter....Pages 241-241
Advances in the Understanding of EBV Associated Lymphoproliferative Disorders....Pages 243-272
The Association of Epstein-Barr Virus with Lymphoproliferative Disorders: A Re-evaluation Using the Polymerase Chain Reaction....Pages 273-276
Absence of EBV in Reed-Sternberg Cells in Many Cases of Hodgkin’s Disease....Pages 277-281
Front Matter....Pages 241-241
EBV and Granular Lymphocytes Proliferation....Pages 283-287
EBV Transmission and Expression among Patients with PTLD....Pages 289-293
SCID Mouse Model of Virus-Induced Lymphomagenesis of Immunodeficient Humans....Pages 295-300
Patients with Psoriasis Have High Serum Reactivity with EBNA-2B....Pages 301-304
EBV Activation By Anti-IgG-Triggered, Second Messenger Pathways....Pages 305-309
Front Matter....Pages 311-311
Nasopharyngeal Carcinoma: 1990....Pages 313-330
 In Situ Analysis of Epstein-Barr Viral Expression in Nasopharyngeal Carcinoma....Pages 331-338
Interaction of EBV Genes with Human Epithelial Cells....Pages 339-345
Studies on the Terminal Protein 1 (TP1) of the Epstein-Barr Virus and the ANTI-TP Immune Response in Humans....Pages 347-351
Diagnosis of Nasopharyngeal Carcinoma Using the Epstein-Barr Virus Coded Alkaline Dnase, Membrane Antigen and Thymidine Kinase....Pages 353-356
Detection of Anti-Epstein Barr Virus Transactivator (Zebra) Antibodies in Sera From Patients With Nasopharyngeal Carcinoma....Pages 357-363
EBV PP58 and DNase Expressed in the Baculovirus System May Improve the Diagnosis of NPC....Pages 365-369
Efficacy of Exfoliative Cytology in Diagnosis of Nasopharyngeal Carcinoma....Pages 371-375
Neoadjuvant Approach with Bleomycin, Epirubicin and Cisplatin in the Treatment of Locally Advanced UCNT....Pages 377-381
Front Matter....Pages 383-383
Pathogenesis of Nasopharyngeal Carcinoma....Pages 385-390
EBV Genome Organization in Lymphoblastoid Cell Lines Established Following Enhancement With Aflatoxin B1 and Relevance to Nasopharyngeal Carcinoma....Pages 391-405
Preliminary Results of HLA Class I and Class II Antigens in Chinese with Nasopharyngeal Carcinoma ◊ ....Pages 407-411
Radiation Therapy of Nasopharyngeal Cancer in Taiwan University Hospital 1958–1989....Pages 413-416
Chemotherapy in Undifferentiated Type Nasopharyngeal Carcinoma (UCNT)....Pages 417-420
Neoadjuvant Chemotherapy Plus Radiotherapy Versus Radiotherapy Alone in Nasopharyngeal Cancer....Pages 421-425
Front Matter....Pages 383-383
The Role of Surgery in the Management of Recurrent Primary Nasopharyngeal Carcinoma....Pages 427-430
Randomized Controlled Studies on Immunotherapy of Nasopharyngeal Carcinoma with OK-432....Pages 431-434
A Preliminary Study on the Immunogenicity in Rabbits and in Human Volunteers: Recombinant Vaccinia Virus Expressing Epstein-Barr Virus Membrane Antigen....Pages 435-439
Back Matter....Pages 441-455